retatrutide safety profile Diagram showing the mechanism of action of Is Retatrutide Safe for Women?

Market analysts anticipate eight or more novel GLP-1-based approvals for chronic weight management over the next four years, as the drug class extends from its metabolic origins into a broader platform for addressing diseases with underlying inflammatory and cardiometabolic components

On 21 May 2026 , Lilly published the long-awaited topline results from the TRIUMPH-1 Phase 3 trial, and the data is striking: participants on the highest dose lost an average of 28.3% of their body weight at 80 weeks , with 45.3% of patients losing 30% or more a threshold previously only achievable with bariatric surgery

The meal plan above tells you what to eat

That said, the limited review history means this is still a provider best approached with awareness rather than blind trust